At a glance
ClinicalIndex Comparison RecordN/ACompleted· 7,124 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post-Licensure Safety Study of ISENTRESS™ in a US Managed Care Network
In Brief
An observational study for HIV-1 Infections. Completed, enrolled 7,124 participants.
Detailed Summary
The objective of this study is to monitor Health Outcomes of Interest (HOI) in participants with human immunodeficiency virus-1 (HIV-1) infection following treatment with Raltegravir.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHIV-1 Infections
Countries--
CollaboratorsKaiser Permanente
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2009
First PostedMar 2010
Primary CompletionDec 2014
TodayJul 2026
First PostedMar 2, 2010
Enrollment StartAug 31, 2009
Primary CompletionDec 9, 2014
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 16.3 years ago